Indian Pharmacopoeia Commission, Jharkhand State Pharmacy Council collaborate for promotion of rational use of medicines

Published On 2025-11-17 06:00 GMT | Update On 2025-11-17 06:00 GMT

New Delhi: The Indian Pharmacopoeia Commission (IPC), Ghaziabad, an autonomous institution under the Ministry of Health and Family Welfare, Government of India, has signed a Memorandum of Understanding (MoU) with the Jharkhand State Pharmacy Council (JSPC), to strengthen collaborative efforts aimed at promoting the safe and rational use of medicines, enhancing pharmacovigilance and materiovigilance activities, and advancing patient safety initiatives across the state of Jharkhand.

The MoU was signed by Dr. V. Kalaiselvan, Secretary-cum-Scientific Director, IPC, and Shri Prasanth Kumar Pandey, Registrar-cum-Secretary, JSPC, in the presence of representatives from both organisations.

Through this collaboration, IPC and JSPC will work together to build the capacity of registered pharmacists in areas related to adverse drug reaction (ADR) reporting, pharmacovigilance and materiovigilance practices, and the safe use of medicines.

The partnership envisions strengthening the utilization of the National Formulary of India (NFI) as a standard reference document across healthcare facilities in Jharkhand and promoting its systematic use by pharmacists to support rational dispensing and safe medication practices. It further includes coordinated efforts to organise awareness programmes for hospital and community pharmacists, support the mandatory use of the NFI in institutional pharmacy settings, and facilitate annual observance of the National Pharmacovigilance Week in collaboration with IPC.

This MoU is expected to enhance professional engagement, encourage wider participation in ADR reporting, and reinforce medicine safety surveillance mechanisms in the state. IPC will provide technical guidance and expert support for these initiatives, while JSPC will coordinate with pharmacists in public and private healthcare establishments to ensure effective implementation of the agreed activities.

The collaboration between IPC and JSPC reflects a shared commitment to improving medication safety and strengthening public health systems through structured capacity-building and the promotion of evidence-based pharmacy practice.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Indian Pharmacopoeia Commission, Jharkhand State Pharmacy Council collaborate for promotion of rational use of medicines

Similar News

Marksans Pharma UK arm gets MHRA nod for Mefenamic Acid Film-Coated Tablets

Lupin secures S&P Global ESG Score of 91 for 2025

JP Nadda inaugurates 10 new AMRIT pharmacies

Bristol Myers Squibb, JnJ stop Phase 3 Librexia ACS trial evaluating milvexian

Pfizer completes acquisition of Metsera

Sanofi Teizeild recommended for EU approval by CHMP for stage 2 type 1 diabetes

Dr Reddy's Told to Justify Patient Numbers in Vonoprazan Phase IV Trial, Revise Protocol